Loading clinical trials...

The Potential of Radiomics to Differentiate Between Malignant and Benign Bosniak 3 Renal Cysts. | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT03552497

The Potential of Radiomics to Differentiate Between Malignant and Benign Bosniak 3 Renal Cysts.

More than 200,000 new cases of renal cancer are diagnosed in the world each year, with more than 63,000 new cases in Europe alone. Of those, renal cell carcinoma (RCC) is the most common type in adult...

Lead sponsor: Maastricht University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment500

Start dateAug 2018

Last updatedApr 6, 2020

Condition

Renal Cyst Complex

Locations shown

Maastricht University Medical Center

Maastricht, Limburg

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 6, 2020Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions